STIMULI : A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

TwoPhase Two

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Radiotherapy,Systemic therapy | LungLung,Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase II trial is evaluating the efficacy (how well the treatment works) and tolerability (how severe the side effects are) of the standard treatment (chemotherapy and radiotherapy) alone and in combination with immunotherapy drugs (nivolumab and ipilimumab) in patients with limited small cell lung cancer (SCLC).
 

This trial is treating patients with limited small cell lung cancer (SCLC).

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy

Commercial Sponsor

Bristol-Myers Squibb (BMS)

Other Non-Commercial Sponsor

Ludwig Institute for Cancer Research

Summary

In this trial, participants will be randomised to the experimental treatment or observation arm. In the experimental arm, participants will receive Nivolumab (1mg/kg IV) and Ipilimumab (3mg/kg IV) as induction therapy once every three weeks for four cycles, followed by 240mg Nivolumab IV as maintenance therapy once every two weeks for a maximum of 12 months.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next